erdosteine molecule mucolytic activity structurally thiol derivative characterized presence two thiol two functional sulfhydryl groups contained molecule released following firstpass metabolism conversion erdosteine pharmacologically active metabolite meti molecule discovered developed italy edmond pharma today prescribed chronic acute respiratory disorders countries worldwide drug sold several commercial names esteclin erdomed erdos erdotin etc hard capsules mg dispersible tablets mg granulates oral suspension mg powder oral suspension erdosteine oral mucoactive antioxidant molecule characterized multifaceted pharmacological profile may positively interfere one pathological processes ongoing respiratory disorders characterized thickened increased mucus production increased oxidative stress chronic inflammation moreover important feature pharmacological profile erdosteine represented synergy antibiotics erdosteine exerts role antioxidant antiinflammatory thanks free sulfhydryl groups active metabolite met direct scavenging effect particularly reactive oxygen species ros able bind free radicals preventing tissue damage erdosteine exerts protective role lipid peroxidation smokers copd patients increasing availability endogenous antioxidants glutathione plasma broncoalveolar lavage erdosteine able interfere bacterial adhesion fact met affect integrity natural intrachain disulphide bonds pilin opening bond induce morphological change interferes binding bacterial adhesin fimbriae receptor bacterial adhesion reduction reached met ad concentration similar plasmatic peak obtained single mg oral administration erdosteine erdosteine showed vivo vitro synergistic activity antibiotics bacterial adhesiveness patients respiratory several clinical studies underline given combination antibiotics erdosteine interfere activity improve effects causing increase therapeutic efficacy erdosteine shows important mucoregulatory activity increases mucus production makes fluid much less thick positively influences mucociliary several studies show erdosteine results active compared mucoregulatory drugs nacetylcysteina sobrerol evidence obtained patients stable chronic bronchitiscopd mucus hypersecretion show erdosteine bring therapeutic advantages longterm administration longterm treatment erdosteine months significantly decrease risk exacerbations hospitalizations improve patients quality life data agreement recent indications international support use mucoactive agents patients hypersecreting chronic pulmonary diseases especially winter months metanalysis conducted patients demonstrated erdosteine brings symptoms improvement reduces risk exacerbations chronic bronchitis copd furthermore erdosteine demonstrated reduce exacerbation duration hospitalization risk due copd restore study reducing exacerbations symptoms treatment oral erdosteine copd multinational randomized doubleblind placebocontrolled study evaluate efficacy safety erdosteine mgbid added usual maintenance therapy vs placebo period long enough avoid bias due seasonal variability exacerbation study patients moderatetosevere stable copd randomized treated hospitalbased pulmonary clinics european countries year treatment reduction exacerbation rate erdosteine treatment result mainly driven reduction rate mid exacerbations equal furthermore erdosteine treatment associated decrease exacerbation duration compared placebo exacerbation rate duration significant differences among inhaled corticosteroids taking nontaking patients registered restore subanalysis demonstrated adding erdosteine maintenance therapy reduces number mild exacerbations duration exacerbations patients moderate metanalysis conducted patients moderate copd shows efficacy safety profile erdosteine superior mucoregulatory drugs carbocysteine nacetylcysteine furthermore erdosteine mucolytic able reduce risk hospitalization due copd several studies demonstrate efficacy erdosteine treatment bronchiectasis terms facility several countries world erdosteine approved bronchiectasis treatment erdosteine shown benefits also treatment chronic rhinosinusitis nasal polyposis otitis media erdosteine tested pediatric patients lower tract respiratory disorders association ampicillin demonstrating high symptoms pediatric population acute bronchitis tracheobronchitis pneumonia erdosteine showed significantly high reduction cough intensity improvement clinical symptoms good erdosteine administered single doses mg mg adult volunteers shows linear kinetic met serum concentration approximately higher erdosteine pharmacokinetic parameters erdosteine met fully comparable single multiple doses therefore accumulation metabolic activation repeated administrations food significantly affect absorption erdosteine oral administration erdosteine rapidly absorbed gastrointestinal tract plasmatic peak concentration cmax reached minutes tmax consumption molecule rapidly transformed firstpass metabolism biologically active metabolite met drug bioavailability oral route good halflife hours plasma binding protein respect pharmacokinetics special populations study health volunteers mean age years confirmed pharmacokinetic parameters erdosteine met similar observed younger adults mean age moderate renal dysfunction elder volunteers affect erdosteine met rats high mgkg clinical studies patients demonstrated erdosteine effective treatment acute chronic infections upper lower respiratory tract mucus hypersecretion modules sputum viscosity respiratory tract making fluid less thick bringing increase mucociliary rate allows mucus removal respiratory tract erdosteine used mucolytic fluidifying agent upper lower respiratory disorders modules sputum viscosity erdosteine efficacy significant reducing symptoms associated chronic obstructive pulmonary multicentric multinational study patients copd demonstrated erdosteine able reduce frequency duration symptomatic exacerbations typical gold global initiative chronic obstructive lung disease international guidelines indicate regular treatment mucolytic like erdosteine reduce exacerbations improve health status patients countries erdosteine approved treatment bronchiectasis data post marketing surveillance confirm erdosteine well tolerated excellent safety profile frequency severity adverse effects clinical studies patients clinical studies low comparable placebo erdosteine stable hydrolysis acid environment direct effect gastric mucus implies good safety profile less patient expected gastrointestinal undesirable effects rare adverse events headache dyspnea taste alterations nausea vomiting diarrhea epigastric pain drug contraindicated subjects hypersensitivity active substance excipients contraindicated subjects active peptic ulcer possible interference product methionine metabolism drug contraindicated patients hepatic cirrhosis deficiency cystathioninesynthetase enzyme harmful interactions drugs reported product therefore administered together antibiotics bronchodilators cough httpsenwikipediaorgwikierdosteine